Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Overview
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Companies Involved in Therapeutics Development
DepYmed Inc
Kaneq Bioscience Ltd
OliPass Corporation
Preveceutical Medical Inc
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Drug Profiles
Antisense Oligonucleotides to Inhibit PTP1B for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit PTP1B for Type 2 Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPT-157633 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPM-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KQ-791 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-009629 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PTP1B for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PTP1B for Rett Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PTP1B for Type 2 Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PTP1B for Type 2 Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trodusquemine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XWJ-24 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Dormant Products
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Discontinued Products
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Product Development Milestones
Featured News & Press Releases
Sep 23, 2019: PreveCeutical announces the successful engineering & cell-based efficacy screening of its Smart-siR constructs for its dual gene therapy research program
Jun 17, 2019: PreveCeutical announces further positive results from its dual gene therapy research program
Jun 27, 2018: Progress toward improved Wilson’s disease drug
May 27, 2014: DepYmed Announces Validation of Trodusquemine as a Therapeutic Candidate for HER2-positive Breast Cancer
Jul 10, 2013: Local foundation raises $15,000 for breast cancer research at Cold Spring Harbor Laboratory
Sep 29, 2011: Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity
Feb 10, 2009: Geera Presents Prelimiry Phase 1b Data For Trodusquemine (MSI-1436)
Jan 22, 2009: Geera Presents Promising Preclinical Data For Trodusquemine (MSI-1436) At Keystone Symposia
Dec 01, 2008: Geera Begins Phase 1b Trial Of Trodusquemine (MSI-1436) In Overweight And Obese Type 2 Diabetics
Oct 06, 2008: Geera Corporation Reports Phase 1 Data For Trodusquemine (MSI-1436) At The North American Association For The Study Of Obesity Annual Meeting
Jul 25, 2008: Geera Releases Phase 1 Data And New Preclinical Data On The CNS Function Of Trodusquemine (MSI-1436) At CBI Obesity Summit
Jul 14, 2008: Geera Corporation Presents Data On Mechanism Of Inhibition Of PTP-1B For Trodusquemine (MSI-1436) At Federation Of American Societies For Experimental Biology (FASEB) Meeting
Jun 09, 2008: Geera Corporation Presents Additiol Promising Preclinical Type 2 Diabetes Data For Trodusquemine (MSI-1436) At American Diabetes Association
Mar 28, 2008: Geera Corporation Announces MSI-1436 Data Presented At Society Of Neuroscience Meeting
Jan 24, 2008: Geera Corporation Presents Promising Preclinical Type 2 Diabetes Data For Trodusquemine (MSI-1436) At Keystone Symposia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by DepYmed Inc, H2 2019
Pipeline by Kaneq Bioscience Ltd, H2 2019
Pipeline by OliPass Corporation, H2 2019
Pipeline by Preveceutical Medical Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019